Trial Profile

A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

Most Recent Events

08 Mar 2019 Status changed from active, no longer recruiting to completed, according to the results published in the Investigational New Drugs
08 Mar 2019 Results published in the Investigational New Drugs
18 Dec 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com